ERNA - Ernexa Therapeutics Inc.
Ernexa Therapeutics Inc. , a preclinical-stage company, develops induces derived mesenchymal stem cells (iMSC) therapies for the treatment of solid tumors and autoimmune disease. The company's lead product is ERNA-101, an allogenic pro-inflammatory cytokine (IL-7/IL-15) secreting iMSC for the treatment of ovarian cancer; and ERNA-102, an anti-inflammatory cytokine (IL-10) secreting iMSC for the treatment of rheumatoid arthritis.
- Sector
- Healthcare
- Industry
- Biotechnology
- Market Cap
- $3.5M
- Beta
- 1.89
- 52-Week Range
- 3.18-90
- CEO
- Sanjeev Luther
- Employees
- 6
- IPO Date
- Aug 29, 1991
- Exchange
- NASDAQ
ERNA Options Snapshot
Options pricing data for ERNA is refreshed daily after the close. When listed contracts exist, this page surfaces the latest at-the-money implied volatility, max pain strike, dealer gamma exposure (GEX), and 25-delta skew. Listed contracts and live snapshots appear once the options chain has been published by the exchange for the most recent session.
What This Page Covers
The ERNA overview links into per-metric analysis views: max pain, gamma exposure, volatility skew, expected move, options chain, open interest history, and aggregate Greeks. Microstructure data is available on short interest, short volume, fail-to-deliver, and market structure. Corporate data is on fundamentals, earnings, analyst ratings, and insider trading.
Frequently asked ERNA overview questions
- What is ERNA?
- ERNA is the ticker symbol for Ernexa Therapeutics Inc., a listed security. Ernexa Therapeutics Inc. , a preclinical-stage company, develops induces derived mesenchymal stem cells (iMSC) therapies for the treatment of solid tumors and autoimmune disease. Listed on NASDAQ. ERNA is the equity ticker shown on this page; equity options traders use the security for directional, volatility, and income strategies via the listed options chain.
- What are ERNA's key statistics?
- Ernexa Therapeutics Inc. (ERNA) carries a market capitalization of $3.5M, beta of 1.89 relative to the broader market, 52-week range of 3.18-90. Full income statement, balance sheet, cash flow, and TTM ratio history is on the per-ticker fundamentals page; daily price history and 52-week levels are accessible from the same view. These structural inputs frame how the options market prices implied volatility around earnings windows and capital events.
- What sector or industry does ERNA belong to?
- Ernexa Therapeutics Inc. operates in the Healthcare sector, in the Biotechnology industry. Sector classification affects how the ticker correlates with sector ETFs, how it reacts to macro factors like rate moves and commodity prices, and how its options pricing compares to sector peers. Compare ERNA's implied volatility and skew against sector benchmarks to gauge whether the options market is pricing single-name or systemic risk relative to the broader peer group.
- How current is the ERNA data on this page?
- Options snapshots refresh after each trading session; if no snapshot is currently posted for ERNA, it usually reflects low options liquidity or a recently listed name. Company-profile fields (sector, industry, market cap, P/E, IPO date) refresh from the vendor feed nightly. Financials and earnings refresh as 10-K and 10-Q filings are parsed (typically within several business days of the actual report). FINRA microstructure data refreshes on the source's cadence (daily for short volume, bi-monthly for short interest, weekly for the OTC volume file, twice-monthly for SEC FTD).